Oniria Therapeutics

We are delighted to announce we’ve completed a seed funding round of €1,28M led by Fundación Botín with participation from BStartup of Banco Sabadell. This will allow the company to continue advancing development of #ONR001, a first-in-class drug for eliminating persistent tumour cells that remain after conventional treatment. We are so grateful to the investors, Vall d'Hebron Institute of Oncology (VHIO), Universitat de Barcelona - Fundació Bosch i Gimpera and Institució Catalana de Recerca i Estudis Avançats, ICREA for believing in Oniria Therapeutics. Press release: https://lnkd.in/ex5n4HAe 📷 Xavier Barril, Carles Galdeano, Esther Riambau, Josep Tabernero MD, PhD, Hector G Palmer and Isabel Puig Borreil, PhD, founders of Oniria Therapeutics. #cancer #CancerPersistence #PrecisionOncology #biotechnology #health

⭐ Congratulations to our Co-Founders Esther Riambau and Isabel Puig Borreil, PhD for being named #Top10MujeresEmprendedoras of Catalonia by EAE Business School, an initiative to highlight female entrepreneurial talent and empower their vision and leadership by providing useful solutions for society. Esther has 19 years of experience in #TechTransfer in the healthcare field. She has helped over 150 projects contributing on business plans elaboration, private and public seed fundraising and team building. Under her leadership as Oniria Therapeutics CEO and Board Member, we work to translate hard-won knowledge on #cancer cell resistance to advanced treatments for patients 💙 Isabel is a passionate about discovering new targets for developing innovative drugs to treat #CancerResistance. She is strongly committed to translating this science into the clinic for oncology patients’ benefit 🧡. Since 2009 she has been a researcher at Vall d'Hebron Institute of Oncology (VHIO) and since 2024, she has also served as Science Research Director at Oniria Therapeutics. We love Isabel because she is driven and resourceful, always stays positive and is resilient in the face of new challenges. 📷 Yesterday’s gala at EAE Business School Barcelona #WomenEntrepreneurshipDay #STEMWomen #WomenInBusiness

🦠 #Sabiesque gairebé el 90% de les morts per càncer es deuen a recaigudes o resistència als tractaments? ✅ Oniria Therapeutics ofereix ONR-001, un fàrmac oral innovador que sobreactiva el supresor tumoral TET2, induint la mort de les cèl·lules canceroses. En assajos preclínics, ha mostrat alta eficàcia i bona tolerabilitat en melanoma, tumors colorectals i leucèmia mieloide aguda. 🔁 Mentre que la majoria dels tractaments dirigits per oncologia posen el focus en inhibir el que no funciona, des d'Oniria Therapeutics aposten per l'activació del sistema de la pròpia cèl·lula que funciona correctament i intentar reprogramar l'estadi tumoral. 💡 El seu projecte és un clar exemple d'innovació disruptiva amb un fort component d'impacte social positiu. Precisament per això, Oniria Therapeutics és una de les #CataloniaExponential Leaders 2024 juntament amb BlindStairs, Cuatrecasas, Magnetika, Navozyme™, Ocean Ecostructures, Suara Cooperativa, SCENT XP (Puig), Time is Brain i UOBO. Vols conèixer les empreses més disruptives de Catalunya? No et perdis el vídeo 📹 💥 https://lnkd.in/d98hzX68

Amazing talk about #ONR001, our first-in-class molecule that activates TET2 and significantly inhibits tumor progression in #leukemia cells and metastatic #melanoma models, by David Aguilar Recarte, PhD, Torres Quevedo Postdoctoral Researcher of Oniria Therapeutics, at the 19th ASEICA - Asociación Española de Investigación sobre el Cáncer Congress. These preclinical findings position ONR-001 as a promising new #CancerPersistence therapy. The #ASEICACongress continues until tomorrow in Zaragoza, Spain with over 400 international cancer scientists 🔝

This week Oniria Therapeutics, represented by our CEO Esther Riambau, is one of the 2,600 companies attending #BIOEurope in Stockholm ♥️ Congrats EBD Group for 30 years of facilitating deal-making and investment in the life sciences industry! #PrecisionOncology #CancerPersistence #cancer #ONR001

The 36th edition of the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics take place this week in Barcelona. David Aguilar Recarte, PhD and Iris María Marcote Corral are presenting a poster (PB102) about the molecular mechanism of action of our first-in-class TET2 activator, #ONR001, a small molecule that strongly inhibits tumor progression in #leukemia cells and in a in vivo model of metastatic #melanoma 👇🏼👏🏼 These results make our drug candidate an attractive and novel therapeutic strategy to fight #cancer. Organised by EORTC - European Organisation for Research and Treatment of Cancer, National Cancer Institute (NCI) and American Association for Cancer Research #ENASymp24 #DrugDevelopment #CancerPersistence #PrecisionOncology #oncology

Oniria Therapeutics ha rebut un Cupó d’ACCIÓ 2024 (Generalitat de Catalunya) en la modalitat de Programes Europeus R+D+I. Agraïts pel suport que representa per accedir a convocatòries d'ajuts de l’European Commission. #CuponsACCIÓ #innovació

🔬 Uno de los grandes retos de la investigación en cáncer y la medicina es evitar las recaídas y la reaparición del cáncer. Por eso, en la Asociación Española Contra el Cáncer estamos apoyando, entre otras, una investigación innovadora que pretende acelerar el desarrollo de un fármaco que evite la recurrencia y recaída del cáncer. 👇 A continuación, te explicamos los detalles de esta investigación que inició hace 14 años la Dra. Isabel Puig, de la mano de la Asociación, y que seguimos apoyando. https://lnkd.in/dm6fT4yV #Investigandoencáncer #TodosContraElCáncer #WorldCancerResearchDay

An amazing week in Boston with the #Jump4Women delegation of entrepreneurs, organized by Foment del Treball Nacional and U.S. Consulate General Barcelona. We are grateful for the opportunity to present the therapeutic solutions being developed by Catalan start-ups to enhance global #health, in discussions with Mayor Michelle Wu, Segun Idowu, head of Economic Opportunity and Inclusion, and key players from the innovation ecosystem, including the MOITI Massachusetts Office of International Trade and Investment, Massachusetts Institute of Technology, Harvard University, Harvard Innovation Labs, MassChallenge, InnoVenture Labs , LabCentral, Engine Ventures, and others. Special thanks also to Tech Barcelona, LEVEL Airlines, and RCD for their support. Learn more about this trip in the media: https://lnkd.in/deZrGrNT #PrecisionOncology #CancerPersistence #biotech

💥 Oniria Therapeutics has been named one of the 10 most disruptive companies by the Government of Catalonia (ACCIÓ). For us, receiving this recognition as #CataloniaExponential Leaders reinforces our mission to have a positive impact on society through #PrecisionOncology. It is also an excellent opportunity to enjoy the benefits of being part of this community (BlindStairs | Tech-Driven Equity in Recruitment , Cuatrecasas, Magnetika, Navozyme™, Ocean Ecostructures, scentXP, Suara Cooperativa, Time is Brain, UOBO, among other startups and companies in recent years). Read press release: https://lnkd.in/dw_UtrNs 📸 #ExponentialDay24, held today at AXA Auditorium in Barcelona. #innovation